Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientifi... (treatment and were maintained over one y...)

HOME >> BIOLOGY >> TECHNOLOGY

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

Date:6/6/2009

treatment and were maintained over one year.

Results from the three other Phase 3 trials (NB-301, NB-303, NB-304) are expected to be announced in the third quarter of 2009. Pending positive results, the Company is on track to submit a New Drug Application (NDA) with the FDA in the first half of 2010.

About NB-302

NB-302 was a 56-week, double-blind, placebo-controlled trial, conducted in 793 patients at nine U.S. centers. The trial evaluated the additional weight loss of Contrave (32mg naltrexone SR/360mg bupropion SR) when added to an intensive behavior modification program consisting of counseling, diet and exercise. The co-primary endpoints were percent change in total body weight from baseline and proportion of patients who lost at least 5% of their baseline body weight.

Based on pre-specified intent-to-treat and completer analyses, obese patients treated with Contrave lost an average of 20.3 pounds to 25.0 pounds, or 9.3% to 11.5% of their baseline body weight, versus 11.0 pounds to 16.0 pounds, or 5.1% to 7.3% of baseline body weight, for patients treated with placebo. In addition, in the categorical weight reduction analysis, the percentage of patients who lost greater than or equal to 10% of their body weight was 41.5% in the Contrave group, compared to 20.2% in the placebo group. Furthermore, 29.1% of patients lost greater than or equal to 15% of their body weight in the Contrave group; compared to 10.9% in the placebo group. All of these findings were highly statistically significant (p< 0.001).

"NB-302 demonstrates that Contrave delivers greater weight loss to patients when added to a rigorous behavioral intervention program compared to the intervention program alone, underscoring the important role of pharmacotherapy as part of a weight management program," said Michael Narachi, President and Chief Executive Officer, Orexigen Therapeutics. "These data
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Post Your Comments:

(Date:12/15/2009)... Medical, Inc. (OTC Bulletin Board : AEMD) announced ... Comper have joined the Science Advisory ... Schorey and Dr. Comper are leading researchers in ... of Aethlon Medical, was recently formed to leverage ... being advanced as an adjunct therapy for Hepatitis-C ...

(Date:12/15/2009)... Mosaic Company (NYSE: MOS ) plans to ... and financial tables on Tuesday, January 5, 2010, after ... Exchange. Results will be available on Mosaic,s website ... a conference call with presentation slides on Wednesday, January ... will begin at 11:00 a.m. Eastern Standard Time (10:00 ...

(Date:12/15/2009)... N.Y., Dec. 15 On January 20th, ... Society for Medical Publication Professionals (ISMPP) will be ... London, UK. More than 100 attendees are expected ... for publication professionals, editors, publishers, medical writers and ... medical publications and the impact of guidelines and ...

(Date:12/15/2009)... has announced the launch of several innovative new programs ... in the current economic climate. The first is ... finance legal services over a period of 6, 12, ... their start-up companies. The second is aimed at ... arrangements over 6 to 12 month period at discounted ...

Breaking Biology Technology:Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2 Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3 Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4 Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5 Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2 Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2 The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2

[0] Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board [0] Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call [0] Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 [0] The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses

... /PRNewswire-FirstCall/,-- Oridion Systems Ltd. - (SWX: ORIDN) ... Anesthesiologists Annual Meeting in San Francisco, CA ... by the,Bernoulli(R) Enterprise system. The MSM system, ... is the only fully integrated,ventilation and oxygenation ...

... ALTO, Calif., Oct. 15 Telik, Inc.,(Nasdaq: ... Drug Administration (FDA),has removed the partial hold on ... a complete review of TELCYTA data by,the agency ... Telik, Inc. of Palo Alto, CA is ...

... ... Volunteers, RESEARCH TRIANGLE PARK, N.C., ... may now be administered with 100mg of ritonavir, an,agent that increases, or ... and Drug Administration approved once-daily LEXIVA 1400,mg with 100mg of ritonavir in ...

Other Biology Technology:Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety 2 Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety 3 Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety 4 FDA Removes Partial Hold on TELCYTA Clinical Development 2 FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 2 FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 3 FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 4

Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety FDA Removes Partial Hold on TELCYTA Clinical Development FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir

(Date:12/15/2009)... 15, 2009 Economics, environmental impacts, social dynamics, ... influence the overall success of an agroecosystem. Positive ... system, forcing individuals and social groups to continuously ... survive. , Experiential learning theory suggests that ... firsthand experiences. Such lessons are especially valuable for ...

(Date:12/15/2009)... Extinct woolly mammoths and ancient American horses may ... several thousand years longer than previously thought. After ... Alaska, a team of researchers used cutting-edge techniques ... in permafrost samples dated to between 7,600 and ... at least one population of these now-extinct mammals ...

(Date:12/15/2009)... German . , Leipzig: Species distribution models ... distribution of mammals. This is the finding of a ... mammals. The researchers analysed data on species distribution, climate, ... information of the species. Judging by the large differences ... seem to adapt fast to changing climatic conditions. This ...

Breaking Biology News(10 mins):Experiential learning teaches change and adaptation 2 Late-surviving megafauna exposed by ancient DNA in frozen soil 2 Late-surviving megafauna exposed by ancient DNA in frozen soil 3 Late-surviving megafauna exposed by ancient DNA in frozen soil 4 Species distribution models are of only limited value for predicting future mammal distributions 2 New Assay Detects 100 Percent of Stage I II and III Colon Cancers in Pre Clinical Trials 14097 1 New Assay Detects 100 Percent of Stage I II and III Colon Cancers in Pre Clinical Trials 14097 2 New Assay Detects 100 Percent of Stage I II and III Colon Cancers in Pre Clinical Trials 14097 3 Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 1 Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 2 Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 3 Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 4 Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 5 Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 6 Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 7 Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 8 Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 1 Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 2 Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 3 Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 4

[0] Experiential learning teaches change and adaptation [1] Late-surviving megafauna exposed by ancient DNA in frozen soil [0] Species distribution models are of only limited value for predicting future mammal distributions

... A group of scientists in Italy have developed a ... that commonly infect humans, according to a study by ... The Journal of Experimental Medicine. Although these fungi pose ... can cause fatal infections in those whose immune systems ...

... developed some clever molecular trickery that is helping to reduce ... in addiction is that neurons in some parts of the ... receptors are important for communication between neurons. The researchers have ... portion of the tail of the glutamate receptor and, once ...

... discovered in tiny snow fleas by Queen's University researchers ... transplantation. , Drs. Laurie Graham and Peter Davies, from ... produced by the fleas to protect themselves against freezing ... Celsius degrees. This would allow organs to be stored ...

Other Biology News:Grabbing addiction by the tail 2 Grabbing addiction by the tail 3 New antifreeze protein found in fleas may allow longer storage of transplant organs 2

Scientists develop fungus-fighting vaccine Grabbing addiction by the tail New antifreeze protein found in fleas may allow longer storage of transplant organs

Prepared in distilled water....

... The RiboGreen RNA Quantitation Kit is ... systems for the quantitation of RNA ... approximately 1000-fold more sensitive than absorbance ... can be detected with fluorescence microplate ...

Request Info...

Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...

Biology Products:

GIBCO MEM Non-Essential Amino Acids Solution 10 mM (100X), liquid from Invitrogen Quant-iT RiboGreen RNA Assay Kit from Molecular Probes (Invitrogen)CometSlide from R&D Systems Caspase-8 Inhibitor Z-IETD-FMK from BioVision

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientifi...(treatment and were maintained over one y...)